Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Recoflavone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 4/20 | 0.58 |
| ▸ | OPRD1 known ✓ | P41143 | 1/20 | 0.56 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.55 |
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.58 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
| ▸ | XDH | P47989 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Recoflavone SCHEMBL29406117 | 0.99 | ABCB1 (0.59) | ABCB1MEN1KMT2AABCG2TP53 | |
| Recoflavone SCHEMBL2483541 | 0.99 | ABCB1 (0.59) | ABCB1MEN1KMT2AABCG2TP53 | |
| Recoflavone SCHEMBL7603767 | 0.98 | ABCB1 (0.58) | ABCB1MEN1KMT2AABCG2TP53 | |
| Recoflavone SCHEMBL4829847 | 0.96 | ABCB1 (0.56) | ABCB1MEN1KMT2AABCG2TP53 | |
| SCHEMBL8427265 | 0.94 | KDM4E (0.59) | ABCB1MEN1KMT2AABCG2TP53 | |
| SCHEMBL7605191 | 0.90 | CYP1B1 (0.72) | ABCB1MEN1KMT2AABCG2TP53 | |
| SCHEMBL2481857 | 0.90 | MEN1 (0.59) | ABCB1MEN1KMT2AABCG2TP53 | |
| SCHEMBL7609527 | 0.90 | KDM4E (0.53) | ABCB1MEN1KMT2AABCG2TP53 | |
| SCHEMBL14178905 | 0.89 | ABCB1 (0.58) | ABCB1MEN1KMT2AABCG2TP53 | |
| SCHEMBL7603078 | 0.89 | L3MBTL1 (0.65) | ABCB1MEN1KMT2AABCG2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8203011-B2 | 3′,4′,5-trimethoxy flavone derivatives as stimulant of mucus secretion, method for the same, and pharmaceutical composition comprising the same | DONG-A PHARM. CO., LTD. (KR) | 2012-06-19 | — | — | US | claimed |
| EP-2170857-B1 | 3',4',5-TRIMETHOXY FLAVONE DERIVATIVES AS STIMULANT OF MUCUS SECRETION, METHOD OF THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG A PHARM CO LTD (KR) | 2011-10-19 | — | — | EP | claimed |
| US-20100130448-A1 | 3',4',5-TRIMETHOXY FLAVONE DERIVATIVES AS STIMULATN OF MUCUS SECRETION, METHOD FOR THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG-A PHARM. CO., LTD (KR) | 2010-05-27 | — | — | US | claimed |
| EP-2170857-A2 | 3',4',5-TRIMETHOXY FLAVONE DERIVATIVES AS STIMULANT OF MUCUS SECRETION, METHOD OF THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Dong-A Pharm.Co., Ltd. (KR) | 2010-04-07 | — | — | EP | claimed |
| EP-1660074-B1 | 7-CARBOXYMETHYLOXY-3 , 4 , 5-TRIMETHOXY FLAVONE MONOHYD RATE, THE PREPARATION METHOD AND USES THEREOF | DONG A PHARM CO LTD (KR) | 2009-12-16 | — | — | EP | claimed |
| WO-2009008632-A2 | GASTRORETENTIVE SYSTEM CONTAINING SOLUBILIZED DRUG FOR MAXIMIZING ITS THERAPEUTIC EFFECT FOR GASTRITIS | DONG-A PHARM. CO., LTD. (KR) | 2009-01-15 | — | — | WO | claimed |
| WO-2008150085-A2 | 3',4',5-TRIMETHOXY FLAVONE DERIVATIVES AS STIMULANT OF MUCUS SECRETION, METHOD OF THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG-A PHARM. CO., LTD. (KR) | 2008-12-11 | — | — | WO | claimed |
| US-7371775-B2 | 7-carboxymethyloxy-3′,4′,5-trimethoxy flavone monohydrate, the preparation method and uses thereof | DONG-A PHARMACEUTICALS CO., LTD (KR) | 2008-05-13 | — | — | US | claimed |
| US-20060178428-A1 | 7-Carboxymethyloxy-3',4',5-trimethoxy flavone monohydrate, the preparation method and uses thereof | DONG-A PHARMACEUTICAL CO., LTD (KR) | 2006-08-10 | — | — | US | claimed |
| US-8203011-B2 | 3′,4′,5-trimethoxy flavone derivatives as stimulant of mucus secretion, method for the same, and pharmaceutical composition comprising the same | DONG-A PHARM. CO., LTD. (KR) | 2012-06-19 | — | — | US | disclosed |
| CN-101684113-B | 7-carboxymethyloxy-3',4',5-trimethoxy flavone monohydrate, the preparation method and uses thereof | DONG A PHARM CO LTD | 2012-05-23 | — | — | CN | disclosed |
| CN-101684113-B | 7-carboxymethyloxy-3',4',5-trimethoxy flavone monohydrate, the preparation method and uses thereof | DONG A PHARM CO LTD | 2012-05-23 | — | — | CN | disclosed |
| EP-2170857-B1 | 3',4',5-TRIMETHOXY FLAVONE DERIVATIVES AS STIMULANT OF MUCUS SECRETION, METHOD OF THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG A PHARM CO LTD (KR) | 2011-10-19 | — | — | EP | disclosed |
| JP-2010138193-A | 7-CARBOXYMETHYLOXY-3',4',5-TRIMETHOXY FLAVONE MONOHYDRATE, PREPARATION METHOD AND USE THEREOF | DONG A PHARM CO LTD | 2010-06-24 | — | — | JP | disclosed |
| EP-1660074-A4 | 7-CARBOXYMETHYLOXY-3 , 4 , 5-TRIMETHOXY FLAVONE MONOHYD RATE, THE PREPARATION METHOD AND USES THEREOF | DONG A PHARM CO LTD (KR) | 2008-02-27 | — | — | EP | disclosed |
| CN-1822829-A | 7-carboxymethoxy-3 ', 4', 5-trimethoxyflavone monohydrate, process for its preparation and its use | DONG A PHARM CO LTD (KR) | 2006-08-23 | — | — | CN | disclosed |
| CN-1822829-A | 7-carboxymethoxy-3 ', 4', 5-trimethoxyflavone monohydrate, process for its preparation and its use | DONG A PHARM CO LTD (KR) | 2006-08-23 | — | — | CN | disclosed |
| US-20060178428-A1 | 7-Carboxymethyloxy-3',4',5-trimethoxy flavone monohydrate, the preparation method and uses thereof | DONG-A PHARMACEUTICAL CO., LTD (KR) | 2006-08-10 | — | — | US | disclosed |
| US-20060178428-A1 | 7-Carboxymethyloxy-3',4',5-trimethoxy flavone monohydrate, the preparation method and uses thereof | DONG-A PHARMACEUTICAL CO., LTD (KR) | 2006-08-10 | — | — | US | disclosed |
| WO-2005023244-A1 | 7-CARBOXYMETHYLOXY-3', 4', 5-TRIMETHOXY FLAVONE MONOHYDRATE, THE PREPARATION METHOD AND USES THEREOF | DONG-A PHARMACEUTICAL CO., LTD. (KR) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178428-A1 | 7-Carboxymethyloxy-3',4',5-trimethoxy flavone monohydrate, the preparation method and uses thereof | SI, MLN, TET2 | MEN1 1448/4885OPRD1 4185/4885HDAC6 3721/4885 |
| US-20100130448-A1 | 3',4',5-TRIMETHOXY FLAVONE DERIVATIVES AS STIMULATN OF MUCUS SECRETION, METHOD FOR THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | TLR5, PTN, TSLP | MEN1 3352/4885OPRD1 2448/4885HDAC6 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.